{
    "nctId": "NCT02139371",
    "briefTitle": "Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography",
    "officialTitle": "64Cu-DOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor) for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Man.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Prostate Cancer, Urinary Bladder Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Biodistribution",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* clinical diagnosis of cancer of prostate, breast or urinary bladder\n* capable of understanding and giving full informed consent\n\nExclusion Criteria:\n\n* pregnancy\n* lactation\n* contraindication for the use of intravenous CT contrast-agencies\n* claustrophobia\n* other current/or former diagnosed cancers, except non melanoma skin cancer or carcinoma in situ cervicis uteri",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}